SEATTLE, May 13, 2021, (MEDGADGET) — Overview:
Inhaling medicine via the respiratory tract is known as pulmonary drug delivery. The drug enters the bloodstream through the lungs’ alveolar wall. Asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis are all treated with drugs administered through the lungs.
Drivers:
Rising cases of chronic obstructive pulmonary disease (COPD) is expected to propel growth of the global pulmonary drug delivery systems market over the forecast period. For instance, According to the report “Chronic Obstructive Pulmonary Disease in Latin America,” reported in the journal Annals of Global Health in January 2019, the prevalence of COPD in Latin American cities ranged from 6.2 to 19.6 percent in people aged 40 and up.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3952
Furthermore, advantages associated with pulmonary drug delivery route are also expected to boost the growth of the market. These benefits include ease of administration, low drug dose compared to oral dosage, relatively few or no side effects, rapid onset of action, prevention of drug degradation by the liver, targeted drug delivery, and a wider absorption area for the lungs.
MDIs held dominant position in the global pulmonary drug delivery systems market in 2019, accounting for 53.9% share in terms of value, followed by DPIs and nebulizers, respectively
Restraints:
Stringent regulatory scenario is expected to hinder growth of the market. Since MDIs and DPIs are considered drug-device combination products and are therefore controlled under new provisions by drug regulatory authorities due to the following factors, regulatory criteria for pulmonary drug delivery systems are very complex:
The combination of individual functions of both the system and the drug formulation is referred to as product output.
- Product operating technique can have an effect on dose administration
- Product production and usage have a substantial environmental impact
Furthermore, a number of mechanical, chemical, and immunological barriers, as well as behavioural barriers such as poor adherence and inhaler technique, all restrict market development.
Opportunities:
R&D in dry powder inhalation is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, researchers from the University of Szeged in Hungary published a paper in June 2020 describing the creation of a carrier-based DPI device, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with a suitable shape and size for pulmonary use.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3952
Furthermore, adoption of vibrating mesh nebulizers for emerging therapeutics is expected to ensure adequate aerosol drug delivery, thereby supporting in growth of the market.
The global pulmonary drug delivery systems market was valued at US$ 28,700.0 Mn in 2019 and is forecast to reach a value of US$ 41,072.7 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.
The global pulmonary drug delivery systems market is estimated to account for US$ 30,005.80 Mn in terms of value in 2020 and is expected to reach US$ 41,072.7 Mn by the end of 2027.
Market Taxonomy:
Pulmonary Drug Delivery Systems Market, By Product Type, is segmented into:
- Nebulizers
- MDIs
- DPIs
By Application:
- Asthma
- COPD
- Cystic Fibrosis
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/pulmonary-drug-delivery-systems-market-3221
Market Trends/Key Takeaways:
Major players in the market are focused on adopting various marketing strategies to enhance their market share. For instance, Glenmark Pharmaceuticals Ltd. received approval from the National Pharmaceutical Pricing Authority (India) for a separate price for its automated dose inhaler, or ‘Digihaler,’ in December 2019.
Launch of devices to track usage of MDIs is boosting growth of the market. For instance, Lupin Ltd. unveiled Adhero, a system that tracks the use of metered-dose inhalers (MDI) by patients with chronic respiratory diseases, in November 2019.
Competitive Landscape:
Major players operating in the global pulmonary drug delivery systems market include, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, 3M Health Care, PARI Respiratory Equipment, Inc., Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim , Omron Healthcare, Inc., Glenmark Pharmaceuticals, and Philips Healthcare.
Key Developments:
Major players in the market are focused on approval and launch of new devices to expand their product portfolio. For instance, Soprobec (beclometasone), a metered-dose aerosol inhaler, and Stalpex (salmeterol/fluticasone), a breath-actuated inhaler, were both launched in April 2019 by Glenmark Pharmaceuticals Ltd.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837